# Cross-sectional Study for Identification and Description of Severe Asthma Patients

> **NCT02293265** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 767 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Short Acting Beta Agonist (SABA)

## Key facts

- **NCT ID:** NCT02293265
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 767 (ACTUAL)
- **Last updated:** 2016-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02293265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02293265, "Cross-sectional Study for Identification and Description of Severe Asthma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02293265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*